Clinical and patient‐reported outcomes from the first 4years of a Psoriasis Biologics Registry in Singapore

Interim analysis of the National Skin Centre Singapore Psoriasis Biologics Registry (SINGPSOR) from August 2017 to May 2021, in which 58 patients were analysed, showing that those receiving biologic treatment had significantly more severe psoriasis based on PASI (Psoriasis Area and Severity Index),...

Full description

Saved in:
Bibliographic Details
Published in:Experimental dermatology 2023-11, Vol.32 (11), p.2023-2028
Main Authors: Xuan Qi Koh, Oon, Hazel H, Wei‐Sheng Chong, Lee, Bernett, Zhao, Xiahong, Tan, Eugene S T
Format: Article
Language:English
Subjects:
Patients
Psoriasis
Statistical analysis
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 2028
container_issue 11
container_start_page 2023
container_title Experimental dermatology
container_volume 32
creator Xuan Qi Koh
Oon, Hazel H
Wei‐Sheng Chong
Lee, Bernett
Zhao, Xiahong
Tan, Eugene S T
description Interim analysis of the National Skin Centre Singapore Psoriasis Biologics Registry (SINGPSOR) from August 2017 to May 2021, in which 58 patients were analysed, showing that those receiving biologic treatment had significantly more severe psoriasis based on PASI (Psoriasis Area and Severity Index), BSA (body surface area) and PGA (Physician Global Assessment) measures at baseline, demonstrated a statistically non‐significant trend towards greater improvement with treatment, and had a lower percentage of adverse events compared to those receiving conventional systemic therapy. Future analyses of SINGPSOR, with larger sample size and longer follow‐up, will be invaluable to further characterize these patients and their treatment outcomes.
doi_str_mv 10.1111/exd.14910
format article
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_2884694285</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2884694285</sourcerecordid><originalsourceid>FETCH-proquest_journals_28846942853</originalsourceid><addsrcrecordid>eNqNjDtOxEAQBUcIJMwn4AYtEXvp8fqbsgIRIiBfjey26ZU9babHEptxBM7ISXDAAXhJBVV6xtxY3Nh1d_TZbWzeWDwxiS0RUyyz4tQk2GCZlhUW5-ZC9YBoq21VJGbajey5dSM438HsIpOPP1_fgWYJkTqQJbYykUIfZIL4TtBz0Aj5kVxQkB4cPKsEdsoK9yyjDNwqvNDAGsMR2MMr-8Gtf3Rlzno3Kl3_8dLcPj687Z7SOcjHQhr3B1mCX9U-q-u8bPKsLrb_q34By0pQRw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2884694285</pqid></control><display><type>article</type><title>Clinical and patient‐reported outcomes from the first 4years of a Psoriasis Biologics Registry in Singapore</title><source>Wiley</source><creator>Xuan Qi Koh ; Oon, Hazel H ; Wei‐Sheng Chong ; Lee, Bernett ; Zhao, Xiahong ; Tan, Eugene S T</creator><creatorcontrib>Xuan Qi Koh ; Oon, Hazel H ; Wei‐Sheng Chong ; Lee, Bernett ; Zhao, Xiahong ; Tan, Eugene S T</creatorcontrib><description>Interim analysis of the National Skin Centre Singapore Psoriasis Biologics Registry (SINGPSOR) from August 2017 to May 2021, in which 58 patients were analysed, showing that those receiving biologic treatment had significantly more severe psoriasis based on PASI (Psoriasis Area and Severity Index), BSA (body surface area) and PGA (Physician Global Assessment) measures at baseline, demonstrated a statistically non‐significant trend towards greater improvement with treatment, and had a lower percentage of adverse events compared to those receiving conventional systemic therapy. Future analyses of SINGPSOR, with larger sample size and longer follow‐up, will be invaluable to further characterize these patients and their treatment outcomes.</description><identifier>ISSN: 0906-6705</identifier><identifier>EISSN: 1600-0625</identifier><identifier>DOI: 10.1111/exd.14910</identifier><language>eng</language><publisher>Chichester: Wiley Subscription Services, Inc</publisher><subject>Patients ; Psoriasis ; Statistical analysis</subject><ispartof>Experimental dermatology, 2023-11, Vol.32 (11), p.2023-2028</ispartof><rights>2023 John Wiley &amp; Sons A/S</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Xuan Qi Koh</creatorcontrib><creatorcontrib>Oon, Hazel H</creatorcontrib><creatorcontrib>Wei‐Sheng Chong</creatorcontrib><creatorcontrib>Lee, Bernett</creatorcontrib><creatorcontrib>Zhao, Xiahong</creatorcontrib><creatorcontrib>Tan, Eugene S T</creatorcontrib><title>Clinical and patient‐reported outcomes from the first 4years of a Psoriasis Biologics Registry in Singapore</title><title>Experimental dermatology</title><description>Interim analysis of the National Skin Centre Singapore Psoriasis Biologics Registry (SINGPSOR) from August 2017 to May 2021, in which 58 patients were analysed, showing that those receiving biologic treatment had significantly more severe psoriasis based on PASI (Psoriasis Area and Severity Index), BSA (body surface area) and PGA (Physician Global Assessment) measures at baseline, demonstrated a statistically non‐significant trend towards greater improvement with treatment, and had a lower percentage of adverse events compared to those receiving conventional systemic therapy. Future analyses of SINGPSOR, with larger sample size and longer follow‐up, will be invaluable to further characterize these patients and their treatment outcomes.</description><subject>Patients</subject><subject>Psoriasis</subject><subject>Statistical analysis</subject><issn>0906-6705</issn><issn>1600-0625</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNqNjDtOxEAQBUcIJMwn4AYtEXvp8fqbsgIRIiBfjey26ZU9babHEptxBM7ISXDAAXhJBVV6xtxY3Nh1d_TZbWzeWDwxiS0RUyyz4tQk2GCZlhUW5-ZC9YBoq21VJGbajey5dSM438HsIpOPP1_fgWYJkTqQJbYykUIfZIL4TtBz0Aj5kVxQkB4cPKsEdsoK9yyjDNwqvNDAGsMR2MMr-8Gtf3Rlzno3Kl3_8dLcPj687Z7SOcjHQhr3B1mCX9U-q-u8bPKsLrb_q34By0pQRw</recordid><startdate>20231101</startdate><enddate>20231101</enddate><creator>Xuan Qi Koh</creator><creator>Oon, Hazel H</creator><creator>Wei‐Sheng Chong</creator><creator>Lee, Bernett</creator><creator>Zhao, Xiahong</creator><creator>Tan, Eugene S T</creator><general>Wiley Subscription Services, Inc</general><scope>7T5</scope><scope>H94</scope></search><sort><creationdate>20231101</creationdate><title>Clinical and patient‐reported outcomes from the first 4years of a Psoriasis Biologics Registry in Singapore</title><author>Xuan Qi Koh ; Oon, Hazel H ; Wei‐Sheng Chong ; Lee, Bernett ; Zhao, Xiahong ; Tan, Eugene S T</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_journals_28846942853</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Patients</topic><topic>Psoriasis</topic><topic>Statistical analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Xuan Qi Koh</creatorcontrib><creatorcontrib>Oon, Hazel H</creatorcontrib><creatorcontrib>Wei‐Sheng Chong</creatorcontrib><creatorcontrib>Lee, Bernett</creatorcontrib><creatorcontrib>Zhao, Xiahong</creatorcontrib><creatorcontrib>Tan, Eugene S T</creatorcontrib><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Experimental dermatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Xuan Qi Koh</au><au>Oon, Hazel H</au><au>Wei‐Sheng Chong</au><au>Lee, Bernett</au><au>Zhao, Xiahong</au><au>Tan, Eugene S T</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical and patient‐reported outcomes from the first 4years of a Psoriasis Biologics Registry in Singapore</atitle><jtitle>Experimental dermatology</jtitle><date>2023-11-01</date><risdate>2023</risdate><volume>32</volume><issue>11</issue><spage>2023</spage><epage>2028</epage><pages>2023-2028</pages><issn>0906-6705</issn><eissn>1600-0625</eissn><abstract>Interim analysis of the National Skin Centre Singapore Psoriasis Biologics Registry (SINGPSOR) from August 2017 to May 2021, in which 58 patients were analysed, showing that those receiving biologic treatment had significantly more severe psoriasis based on PASI (Psoriasis Area and Severity Index), BSA (body surface area) and PGA (Physician Global Assessment) measures at baseline, demonstrated a statistically non‐significant trend towards greater improvement with treatment, and had a lower percentage of adverse events compared to those receiving conventional systemic therapy. Future analyses of SINGPSOR, with larger sample size and longer follow‐up, will be invaluable to further characterize these patients and their treatment outcomes.</abstract><cop>Chichester</cop><pub>Wiley Subscription Services, Inc</pub><doi>10.1111/exd.14910</doi></addata></record>
fulltext fulltext
identifier ISSN: 0906-6705
ispartof Experimental dermatology, 2023-11, Vol.32 (11), p.2023-2028
issn 0906-6705
1600-0625
language eng
recordid cdi_proquest_journals_2884694285
source Wiley
subjects Patients
Psoriasis
Statistical analysis
title Clinical and patient‐reported outcomes from the first 4years of a Psoriasis Biologics Registry in Singapore
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T23%3A14%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20and%20patient%E2%80%90reported%20outcomes%20from%20the%20first%204years%20of%20a%20Psoriasis%20Biologics%20Registry%20in%20Singapore&rft.jtitle=Experimental%20dermatology&rft.au=Xuan%20Qi%20Koh&rft.date=2023-11-01&rft.volume=32&rft.issue=11&rft.spage=2023&rft.epage=2028&rft.pages=2023-2028&rft.issn=0906-6705&rft.eissn=1600-0625&rft_id=info:doi/10.1111/exd.14910&rft_dat=%3Cproquest%3E2884694285%3C/proquest%3E%3Cgrp_id%3Ecdi_FETCH-proquest_journals_28846942853%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2884694285&rft_id=info:pmid/&rfr_iscdi=true